WO2005060984A1 - Method and apparatus for preventing and treating eyelid problems - Google Patents

Method and apparatus for preventing and treating eyelid problems Download PDF

Info

Publication number
WO2005060984A1
WO2005060984A1 PCT/US2003/039573 US0339573W WO2005060984A1 WO 2005060984 A1 WO2005060984 A1 WO 2005060984A1 US 0339573 W US0339573 W US 0339573W WO 2005060984 A1 WO2005060984 A1 WO 2005060984A1
Authority
WO
WIPO (PCT)
Prior art keywords
stimulus
method
applying
eyelid
glands
Prior art date
Application number
PCT/US2003/039573
Other languages
French (fr)
Inventor
Richard W. Yee
Original Assignee
Yee Richard W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yee Richard W filed Critical Yee Richard W
Priority to PCT/US2003/039573 priority Critical patent/WO2005060984A1/en
Publication of WO2005060984A1 publication Critical patent/WO2005060984A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36046Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the eye
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2278Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents

Abstract

A method and apparatus are provided by whicheyelid diseases may be treated and eyelid hygiene may be performed. In particular, the method and apparatus stimulate eyelid muscles (24) and facial muscles, allowing stimulation of glandular eyelid components (20, 22) that allow optimization of the tear film (16) and the ocular surface (14). In this manner, the symptoms associated with ocular irritation or with eyelid disorders may be treated by maintaining proper tear film composition.

Description

METHOD AND APPARATUS FOR PREVENTING AND TREATING EYELID PROBLEMS

BACKGROUND OF THE INVENTION

1. Field Of The Invention The present invention relates generally to the field of ophthalmology and, more specifically, to the field of eyelid hygiene and treatment.

2. Description Of The Related Art This section is intended to introduce the reader to aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.

In the field of ophthalmology, a common patient complaint is of ocular irritation, such as dry-eye, a diagnosis characterized by burning, red eyes, irritation, itching, and vision fluctuations. Symptoms typically result from an insufficiently lubricated ocular surface which increases the shear forces associated with blinking and which reduces the ability of the ocular surface to respond to environmental challenges, such as wind, low humidity, and particulates . The label "dry-eye," however, may be a misnomer as aqueous tear production can be normal in patients with this diagnosis. Instead, dry-eye symptoms are commonly precipitated by a change in the composition of the tear film coating of the eye that may be in itself irritating or that may deviate from the tear film's optimal ocular surface properties, causing an increase in the rate of evaporation of the tear film.

In particular, a lipid component of the tear film may be either reduced or changed in composition, thereby increasing the rate of evaporation. These changes in the lipid layer are often the result of obstructive meibomian gland dysfunction (MGD) , a form of posterior blepharitis that results in changes to the local eyelid margin. _ In particular, obstruction of the meibomian glands may decrease delivery of meibomian gland secretions, which comprise various oil and lipid components and which are typically expelled from the glands upon blinking.

The meibomian glands themselves are a row of enlarged sebaceous glands disposed along the lid margin posterior to the lid lashes. The meibomian glands are found on both the upper and lower lids and produce a holocrine lipid secretion that constitutes the surface layer of the preocular tear film. This lipid surface layer helps produce a smooth optical surface, reduces evaporation, and reduces contamination by skin surface lipids. Despite its importance, the lipid surface layer is believed to comprise only the upper 70 nanometers or so of the 7.0 micron thick tear film.

Structurally, the meibomian glands are generally straight tubules from which saccular acini project. Smooth and skeletal muscle fibers and elastic tissue is found around the acini. In addition, the muscle of Riolan and other periocular skeletal eye muscles are also associated with the glands. Fibers in the muscle of Riolan are arranged around the ducts leading to the orifices of the Meibomian glands and are believed to have a role in the expression of the meibomian gland secretions. In particular, combined movements within the Riolan muscle may compress the meibomian gland ductules, expressing their contents. The periocular eye muscles maintain line tone and the normal apposition of the eyelid margins to the ocular surface providing optimal application of the components of the tear film.

However, when a patient is afflicted with MGD, the meibomian glands may be plugged or partially plugged, typically with yellowish, solidified oil and lipids. In particular, the gland products themselves, i.e. lipids and oils, may solidify within the gland ducts plugging the ducts. Due to the plugging of the ducts, secretory product, as well as the relative bacterial counts, are built up within the gland and sufficient meibomian oils and lipids are not expressed into the tear film, increasing the relative counts of the normal flora of the eye. The solidification of gland products may occur for various reasons such as temperature sensitivity or melting point shifts, hormonal influences, variations in lipid composition, or infection.

Treatment for MGD comprises a regimen of lid hygiene. Typically applying warm compresses to the eyelids, massaging the eyelids, and washing the eyelid using a lid scrub are performed to express the contents of the meibomian glands. While such a regimen may be helpful, it may not be sufficient in acute cases of MGD. In addition, depending on the indications, antibiotics and steroids might also be employed in treatment. A more effective mechanism of lid hygiene, capable of unplugging even severely plugged ducts is therefore desired. The present invention addresses one or more of the concerns set forth above.

BRIEF DESCRIPTION OF THE DRAWINGS The foregoing and other advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings in which:

Figure 1 is a cross-sectional, side-view depicting an eye and eyelids; Figure 2 is a front view of an upper and lower eyelid receiving electrical stimulation; and

Figure 3 is a front view of an upper and lower eyelid receiving chemical stimulation.

DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS One or more specific embodiments of the present invention will be described below. Turning now to the drawings, and referring initially to Fig. 1, a cross-section of an eye 10 and associated eyelids 12 are depicted. The eye 10 comprises an ocular surface 14 which is in contact with a layer of tear film 16. The aqueous phase of the tear film is largely produced by the lacrimal glands 18. Other components of the tear film 16 are produced by various other glands, such as the goblet cells, the gland of Wolfring, and the glands of Krause, which are not depicted for simplicity.

A lipid component of the tear film 16 is produced by the meibomian glands 20. The orifices 22 of the meibomian glands 20 are located on the edges of the eyelids 12. The meibomian gland itself comprises various saclike acini which are surrounded by smooth muscle tissue and the muscle of Riolan 24 which are presumed to aid in the expression of the meibomian gland products. Because of the involvement of the smooth muscle tissue and the muscle of Riolan in the expression of meibomian gland products, stimulation of the various muscle fibers may be employed to express the meibomian gland 20, expelling any obstructing plug 26 which obstructs the orifice 22 to allow the normal flow of meibomian gland secretory products. The obstructing plug 26 may be composed of hardened lipids and oils or cellular debris or some combination thereof.

Stimulation of the appropriate muscles has been found to expel these obstructing plugs 26. For example, in one embodiment of the present invention, an low-intensity, pulsed electrical current is used to induce contraction of the muscle of Riolan 24 or other muscles associated with the meibomian gland 20 or eyelid 12. Referring now to Fig. 2, the use of an electrical current to stimulate muscle contraction is depicted. In particular, electrical contacts 28 are disposed upon the exterior surface of one of the eyelids 12. Lead wires 30 or an equivalent inductive mechanism connect the electrical contacts 28 to a power source 32. As one skilled in the art will realize, the electrical contacts 28 may be loose or may be fixed upon an applicator, such as a wand or other device, such that a constant distance is maintained and the lead wires 30 are not loose. Similarly, the electrical contacts 28 are sized such that they may be simultaneously disposed upon the eyelid 12 to stimulate contractions. In particular, the electrical contacts 28 are each sized to skin contact area of less than 1.5 cm . In one embodiment of the present invention the surface area of each contact 28 is approximately 1.14 cm2.

An electrical current is provided by the power source 32 to the electrical contacts 28, thereby inducing muscular contractions within the eyelid 12. The resulting contractions act to expel any obstructing plugs 26 within the orifices 22 of the meibomian glands 20, allowing the free flow of the normal lipid secretory product. The induced contractions may also cause the secretion or expulsion of other additional beneficial tear film components. Additionally, the resulting stimulation has the added benefit of improving muscle tonus within the eyelid and surrounding facial muscles.

In a typical embodiment, the power supply 32 provides a direct current, typically comprising a pulse wave-form with a pulse basewidth of less than 60 microseconds and a pulse frequency less than or equal to 1 pulse per second. The voltage producing the current is less than or equal to 300 V. The current is generally less than or equal to 1.0 milliamp and is preferably less than or equal to 0.6 milliamps with a resulting power of 0.2 W or less. A current density of less than or equal to 2 milliamps/cm2 and a power density of less than or equal to 3.0 watts/cm2 typically result for the preferred ranges of current and contact 28 surface areas. While the depicted embodiment demonstrates the current being applied to the periocular muscles of the upper eyelid 12, the current may be applied to the periocular muscles of either eyelid 12 or, indeed, to other facial muscles associated with expression.

The application of the current itself may be applied from once a day to several times a day. Further, the applied current may vary between applications so long as an adequate massage or twitching of the eyelid 12 is achieved. The treatment may be continued as long as needed and may be used either as a treatment for obstructive MGD or as a preventative or maintenance measure.

In addition, an alternative embodiment of the present invention, as depicted in Fig. 3, allows for the application of a chemical 34 to stimulate contraction of the muscles associated with the meibomian glands 20. The chemical 34 may be applied topically to the exterior to the eyelid, as depicted, or may alternatively be applied as an eyedrop, thereby stimulating the appropriate muscles, glands or cells from the interior surface of the eyelids 12.

In this embodiment, contraction of the muscles or glands may be accomplished by a variety of neurotransmitters, including various neuropeptides . One such peptide believed to be associated with the contraction of muscles associated with the meibomian glands 20 is vasoactive intestinal polypeptide (VIP) . Application of a VIP containing compound upon the interior or exterior of the eyelids 12 may therefore be employed to stimulate muscle contraction as discussed above. In particular, such a treatment may be employed as needed at dosages sufficient to promote muscle contraction and clearance of any plugs 26 obstructing orifice 22 or as a preventative measure to prevent such plugs 26 from forming. One skilled in the art will recognize that other neuromuscular transmitters may also be employed as an active ingredient to achieve the same efficacy. Additionally, as discussed in regard to electrical stimulation, the secretion or expulsion of other beneficial tear film components and the improvement in tonus within the stimulated region may also result from the chemical stimulation.

While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.

Claims

CLAIMSWhat is claimed is:
1. A method for treating eyelid disorders, the method comprising:
applying a stimulus to one or more facial muscles associated with one or more eyelid glands; and
promoting the expression of a tear film component from the one or more eyelid glands by application of the stimulus.
2. The method of claim 1, wherein applying the stimulus comprises applying a chemical stimulus.
3. The method of claim 2, wherein applying the chemical stimulus comprises applying a vasoactive intestinal polypeptide .
4. The method of claim 2, wherein applying the chemical stimulus comprises applying the chemical stimulus as an eyedrop.
5. The method of claim 1, wherein applying the stimulus comprises applying an electrical stimulus.
6. The method of claim 5, wherein applying the electrical stimulus comprises applying a direct current less than or equal to 1.0 milliamps.
7. The method of claim 1, wherein applying the stimulus to the one or more facial muscles comprises applying the stimulus to one or more periocular muscles.
8. The method of claim 7, wherein applying the stimulus to the one or more periocular muscles comprises applying the stimulus to one or more muscles of Riolan
9. The method of claim 1, wherein promoting the expression of the tear film component from the one or more eyelid glands comprises promoting the expression of a lipid composition from one or more meibomian glands .
10. A composition for preventing eyelid disorders, the composition comprising one or more components which stimulate one or more periocular muscles associated with one or more glands that contribute to the tear film.
11. The composition of claim 10, wherein the one or more components comprise at least one neurotransmitter .
12. The composition of claim 11, wherein the neurotransmitter is vasoactive intestinal polypeptide.
13. The composition of claim 10, wherein the one or more periocular muscles is the muscle of Riolan.
14. The composition of claim 10, wherein one of the one or more glands is a meibomian gland.
15. A device for treating eyelid disorders, the device comprising:
two or more electrical contacts sized to be simultaneously disposed upon an eyelid;
a lead wire attached to each electrical contact;
an electrical power source to which the lead wires connect.
16. The device of claim 15, wherein the power source provides a direct current.
17. The device of claim 16, wherein the direct current is less than or equal to 1.0 milliamps.
18. The device of claim 17, wherein a current density of less than or equal to 2.0 milliamps/cm2 is produced by the direct current.
19. The device of claim 16, wherein the direct current has a pulse waveform.
20. The device of claim 15, wherein the two or more electrical contacts are disposed a fixed distance apart upon an applicator.
PCT/US2003/039573 2003-12-12 2003-12-12 Method and apparatus for preventing and treating eyelid problems WO2005060984A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2003/039573 WO2005060984A1 (en) 2003-12-12 2003-12-12 Method and apparatus for preventing and treating eyelid problems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003296968A AU2003296968A1 (en) 2003-12-12 2003-12-12 Method and apparatus for preventing and treating eyelid problems
PCT/US2003/039573 WO2005060984A1 (en) 2003-12-12 2003-12-12 Method and apparatus for preventing and treating eyelid problems

Publications (1)

Publication Number Publication Date
WO2005060984A1 true WO2005060984A1 (en) 2005-07-07

Family

ID=34709647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/039573 WO2005060984A1 (en) 2003-12-12 2003-12-12 Method and apparatus for preventing and treating eyelid problems

Country Status (2)

Country Link
AU (1) AU2003296968A1 (en)
WO (1) WO2005060984A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2983695A1 (en) * 2011-12-12 2013-06-14 Ludovic Benichou Medical device for contracting and reanimating paralyzed eyelid of patient, has electronic control case to apply electrostimulation current to paralyzed eyelid via output of case and via electrode implanted in muscle of paralyzed eyelid
EP2640461A1 (en) * 2010-11-16 2013-09-25 The Board of Trustees of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US8996137B2 (en) 2013-04-19 2015-03-31 Oculeve, Inc. Nasal stimulation devices and methods
US9265956B2 (en) 2013-03-08 2016-02-23 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9687652B2 (en) 2014-07-25 2017-06-27 Oculeve, Inc. Stimulation patterns for treating dry eye
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
US9737712B2 (en) 2014-10-22 2017-08-22 Oculeve, Inc. Stimulation devices and methods for treating dry eye
US9764150B2 (en) 2014-10-22 2017-09-19 Oculeve, Inc. Contact lens for increasing tear production
US9770583B2 (en) 2014-02-25 2017-09-26 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745100A (en) * 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030225041A1 (en) * 2000-09-22 2003-12-04 Nolan Gerard M. Physiological method of improving vision

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745100A (en) * 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030225041A1 (en) * 2000-09-22 2003-12-04 Nolan Gerard M. Physiological method of improving vision

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIPHAM W J ET AL: "A HISTOLOGIC ANALYSIS AND THREE-DIMENSIONAL RECONSTRUCTION OF THE MUSCLE OF RIOLAN" OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, MASSON, NEW YORK, NY, US, vol. 18, no. 2, 2002, pages 93-98, XP009030825 ISSN: 0740-9303 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143846B2 (en) 2010-11-16 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
EP2640461A1 (en) * 2010-11-16 2013-09-25 The Board of Trustees of The Leland Stanford Junior University Systems and methods for treatment of dry eye
EP2640461A4 (en) * 2010-11-16 2014-11-12 Univ Leland Stanford Junior Systems and methods for treatment of dry eye
US8918181B2 (en) 2010-11-16 2014-12-23 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
US9095723B2 (en) 2010-11-16 2015-08-04 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US10328262B2 (en) 2010-11-16 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
FR2983695A1 (en) * 2011-12-12 2013-06-14 Ludovic Benichou Medical device for contracting and reanimating paralyzed eyelid of patient, has electronic control case to apply electrostimulation current to paralyzed eyelid via output of case and via electrode implanted in muscle of paralyzed eyelid
US9265956B2 (en) 2013-03-08 2016-02-23 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
US10238861B2 (en) 2013-04-19 2019-03-26 Oculeve, Inc. Nasal stimulation devices and methods for treating dry eye
US9737702B2 (en) 2013-04-19 2017-08-22 Oculeve, Inc. Nasal stimulation devices and methods
US9440065B2 (en) 2013-04-19 2016-09-13 Oculeve, Inc. Nasal stimulation devices and methods
US8996137B2 (en) 2013-04-19 2015-03-31 Oculeve, Inc. Nasal stimulation devices and methods
US10155108B2 (en) 2013-04-19 2018-12-18 Oculeve, Inc. Nasal stimulation devices and methods
US9770583B2 (en) 2014-02-25 2017-09-26 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9956397B2 (en) 2014-02-25 2018-05-01 Oculeve, Inc. Polymer Formulations for nasolacrimal stimulation
US9687652B2 (en) 2014-07-25 2017-06-27 Oculeve, Inc. Stimulation patterns for treating dry eye
US9764150B2 (en) 2014-10-22 2017-09-19 Oculeve, Inc. Contact lens for increasing tear production
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
US10112048B2 (en) 2014-10-22 2018-10-30 Oculeve, Inc. Stimulation devices and methods for treating dry eye
US9737712B2 (en) 2014-10-22 2017-08-22 Oculeve, Inc. Stimulation devices and methods for treating dry eye
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies

Also Published As

Publication number Publication date
AU2003296968A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
Bonica Autonomic innervation of the viscera in relation to nerve block
US7799337B2 (en) Method for directed intranasal administration of a composition
US8676324B2 (en) Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US9409028B2 (en) Implantable microstimulators with programmable multielectrode configuration and uses thereof
US8014878B2 (en) Flexible circuit electrode array
Suaning et al. CMOS neurostimulation ASIC with 100 channels, scaleable output, and bidirectional radio-frequency telemetry
US7292890B2 (en) Vagus nerve stimulation via unidirectional propagation of action potentials
GARDNER Cross talk—the paradoxical transmission of a nerve impulse
Matarasso Complications of botulinum A exotoxin for hyperfunctional lines
US4841973A (en) Electrical stimulators
US6491940B1 (en) Apparatus for administering composition for inhibiting cerebral neurovascular disorders and muscular headaches
US8628504B2 (en) Method and apparatus for treating meibomian gland dysfunction employing fluid jet
Young et al. Electrical stimulation of the brain in treatment of chronic pain: experience over 5 years
US20140213842A1 (en) Methods and devices for treating primary headache
US10058704B2 (en) Systems, devices and methods for the treatment of neurological disorders and conditions
Besch et al. Extraocular surgery for implantation of an active subretinal visual prosthesis with external connections: feasibility and outcome in seven patients
US20140039578A1 (en) Implantable microstimulators and methods for unidirectional propagation of action potentials
US10188853B2 (en) Flexible circuit electrode array with a drum stress relief
US4981146A (en) Nausea control device
AU2011343763B2 (en) Devices, systems and methods for the treatment of medical disorders
US5458625A (en) Transcutaneous nerve stimulation device and method for using same
EP2092951A1 (en) Device for electrotherapeutical treatment of tension headaches
US9314615B2 (en) Method of making a flexible circuit electrode array
US7991478B2 (en) Flexible circuit electrode array with at least one tack opening
CN101072602B (en) Apparatus for electrically inhibiting facial muscles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct app. not ent. europ. phase
NENP Non-entry into the national phase in:

Ref country code: JP